Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that breast cancer patients treated with CDK4/6 inhibitors plus endocrine therapy experienced more pronounced vertex hair loss and were less responsive to minoxidil treatment compared to those on endocrine monotherapy.

This review discusses the use of CDK4/6 inhibitors with endocrine therapy in treating women with HR+ HER2- advanced breast cancer, but it reports no new clinical findings.

In this study, the researchers found that different CDK4/6 inhibitors used in treating HR+/HER2- advanced breast cancer have varying safety profiles and impacts on patient quality of life.

This study concluded that while CDK4/6 inhibitors, used to treat HR+ HER2- metastatic breast cancer, generally did not worsen health-related quality of life, they were associated with increased patient-reported issues like diarrhea and hair loss upset.

This study observed that dalpiciclib is associated with fewer adverse events like diarrhea and hepatotoxicity compared to other CDK4/6 inhibitors, potentially offering better patient-perceived safety and quality of life.

This study found that alopecia induced by CDK4/6 inhibitors in breast cancer patients occurs more quickly and is more resistant to minoxidil treatment compared to endocrine therapy-induced alopecia.

This study found that cyclin-dependent kinase 4/6 inhibitors used for metastatic breast cancer caused alopecia resembling androgenetic alopecia, negatively impacting patients' quality of life, but topical minoxidil showed potential for improvement.

This study found that 49% of female breast cancer patients treated with CDK4/6 inhibitors for at least three months developed alopecia, which significantly impacted their quality of life, with greater alopecia severity leading to worse emotional and functional well-being.

This study found that patients, oncologists, and payers prioritize a significant improvement in efficacy to justify the added risks and costs when considering CDK4/6 inhibitors combined with endocrine therapy for early-stage breast cancer.

This study found that the CDK4/6 inhibitor palbociclib may protect human hair follicles from the damaging effects of taxane chemotherapy by inducing G1 arrest in stem/progenitor cells.

This study found that CDK4/6 inhibitors in hormone-positive metastatic breast cancer were linked to increased risks of fatigue, alopecia, and stomatitis compared to placebo.

In this multicentric retrospective study, researchers reported that cutaneous adverse events were common among advanced breast cancer patients treated with cyclin-dependent kinase inhibitors (CDK4/6i), generally mild, and manageable with topical treatments, though in some cases, they led to treatment discontinuation.

This study found that CDK4/6 inhibitors for HR+/HER2- advanced breast cancer are linked to typical adverse events such as fatigue and neutropenia, while also identifying unexpected reactions, highlighting potential safety concerns in their real-world use.

This report details a case of hair, nail, and pigmentary disorders occurring 10 months after starting abemaciclib for metastatic breast cancer, highlighting that cutaneous side effects, although less frequent, can lead to discontinuation in 25% of cases.

This study found that local PGE2 injection may prevent radiotherapy-induced hair loss by protecting hair follicle cells and promoting hair follicle self-repair.

This study found that prostaglandin E2 pretreatment may reduce radiotherapy-induced alopecia by enhancing hair follicle self-repair through transient G1 arrest, suggesting a potential preventive treatment.

This study found that ATP may help reduce ribociclib-induced skin damage in rats by mitigating biochemical changes associated with oxidative stress.

This research found that kaempferol, a flavonoid from hair growth-promoting plants, significantly enhanced human dermal papilla cell proliferation and inhibited specific signaling pathways, outperforming minoxidil, with topical application in mice promoting hair growth and thickness, indicating potential as a natural hair loss treatment.

This study found that costunolide promotes hair growth in both lab-cultured human hair follicle cells and in live mice by modulating growth factor pathways.

In this study, researchers report that CDK inhibitors like palbociclib and ribociclib, initially developed for cancer therapy, show potential in treating neutrophilic inflammation-related conditions such as ARDS and psoriasis, although their clinical repurposing requires further research on safety and dose adjustments.

This review discusses androgen receptor targeting as a potential treatment strategy for triple-negative breast cancer and reports no new experimental outcomes.

This study found that 3-Deoxysappanchalcone may stimulate hair growth in mice by promoting proliferation of hair follicle dermal papilla cells through WNT/β-catenin and STAT signaling modulation.

This study reviewed competing endogenous RNA networks related to skin aging and wound healing, finding mechanisms like UVB-induced senescence and photoaging, as well as potential therapeutic targets for improving skin health and recovery.

In this study, researchers presented cases of cellular neurothekeoma in three male family members with early-onset in infancy, suggesting a potential genetic component and inheritance pattern, which deviates from the typical presentation seen mostly in women between 20–30 years.

This study, using modified Delphi panels, provided consensus recommendations for managing alpelisib-induced hyperglycemia and rash, advising prophylactic metformin starting for certain risk groups and the use of nonsedating H1 antihistamines and topical steroids for initial rash management.

This study conducted in an Iraqi oncology setting found generic Palbociclib to have a safety profile consistent with previous data, with observed side effects including high rates of neutropenia and anemia, particularly among patients receiving it with Fulvestrant.

This study found that the extracts of Serenoa repens, when evaluated through chemical, biological, and in silico methods, demonstrated anti-inflammatory, pro-apoptotic, and anti-androgenic activities against prostate cancer cell lines, suggesting potential therapeutic benefits and directing future pharmaceutical development.

This study developed a DPC cell line by introducing mutant CDK4, Cyclin D1, and TERT, making it a promising tool to study downstream signaling pathways activated by testosterone in androgenetic alopecia.

Mice treatments didn't grow hair, a patient treatment may affect immune response, and people with hair loss often feel anxious or depressed.

This study found that Ishige sinicola extract increased hair growth and cell proliferation in cultured vibrissa follicles and mice, suggesting potential benefits for treating alopecia through β-catenin activation and 5α-reductase inhibition.